News

Clinicians emphasize screening, individualized care, and recognition of sex-based differences to prevent vision-threatening complications

Cataract surgeons discuss their comprehensive approach to IOL counseling

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

EYE PCR’s fixOflex is now eligible for European market introduction, providing clinicians with a method of preserving the capsular bag’s form after cataract surgery.

Experts debate real-world retina cases—mystery vitreous hemorrhage, floater vitrectomy, buckle comeback, PDR laser vs anti-VEGF, GA timing.

The superiority primary endpoint at week 36 was met with high statistical significance, and AXPAXLI showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.

Inder Paul Singh, MD, spoke alongside Mary Qiu, MD, and Danica J. Marrelli, OD, FAAO, AAODip, in a CE Spotlight Symposium at the conference.

Clear counseling and tailored lens choice reduce postoperative dissatisfaction

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

Dry eye care shifts to spectrum-based screening and targeted therapies, from TRPM8 agonists to evaporation shields, with upcoming anti-inflammatories promising faster relief.

FDA clears DifGen’s generic fluorometholone 0.1% eye drop suspension, expanding lower-cost options for anterior eye inflammation and steroid care.

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

A closer look at the science powering next-generation retinal treatments

Reduced tobacco use and access to care are key components

Join Douglas D. Koch, MD, and Liliana Werner, MD, PhD, as they break down acrylic and silicone intraocular lenses, discuss material-specific risks, and explore the future of lens technology in this inaugural episode.

Zarmeena Vendal, MD, discussed the intersections between cataract surgery and glaucoma.

Inder Paul Singh, MD, discusses his practice's approach to office-based surgery.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."

Explore how glaucoma care merges with refractive cataract surgery, covering MIGS choices, ocular surface optimization, and IOL selection to maximize vision quality.

Most eyes were fluid-free after 24 weeks with visual acuity increases observed in some.

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Risk stratification, patch graft selection, tube repositioning, and multidisciplinary care all play a role in minimizing erosion and protecting long-term outcomes.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.